首页> 外文OA文献 >Encapsulation de molécules hydrophobes par des structures bi-gels générées par prilling : relation structure-propriétés
【2h】

Encapsulation de molécules hydrophobes par des structures bi-gels générées par prilling : relation structure-propriétés

机译:造粒产生的双凝胶结构对疏水性分子的包封:结构-性质关系

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

This thesis focuses on the generation and characterization of organo-hydrogel capsules (bigels), manufactured by prilling technology for controlled drug delivery after oral administration. Efavirenz (EFV), an antiretroviral medications used to treat HIV/AIDS, is the active pharmaceutical ingredient (API) used as a model molecule of low solubility in water. It was dissolved in the organogel, which is compound of sunflower oil and 12-hydroxystearic acid (12-HSA). The organogel was characterized by its phase transition temperature sol-gel-sol. The typical thermoreversibility of this organogel has not changed with introduction of EFV. The organogels were produced at two temperatures (5 °C and 25 °C) and with two concentrations of 12-HSA (5% and 20%) for being characterized as an API vehicle. Two dissolution media were used with and without enzymes (pH 1.2 and 6.8), for EFV release quantification. The EFV release profile from bi-gels capsules (diameter from 2500 to 3000 μm) is essentially related to the amount of organogelator in their core, to the presence of the alginate membrane and to the state physics of this membrane (hydrated or dry). The release of EFV has reduced 50% at acid pH in the presence of the external membrane. In simulated gastric fluid, the release is slower than at pH 6.8 (simulated intestinal fluid). In the intestine, the membrane loses its protective function and the organogel’s core begins to control the release of EFV. Two release mechanisms are observed: erosion and diffusion, which can be explained by the Korsmeyer-Peppas model.
机译:本论文的重点是通过造粒技术制造的有机水凝胶胶囊(bigels)的产生和表征,以控制口服后的药物输送。 Efavirenz(EFV)是一种用于治疗HIV / AIDS的抗逆转录病毒药物,是一种活性药物成分(API),被用作在水中低溶解度的模型分子。将其溶解在有机凝胶中,该有机凝胶是向日葵油和12-羟基硬脂酸(12-HSA)的混合物。有机凝胶的特征在于其相变温度为溶胶-凝胶-溶胶。随着EFV的引入,这种有机凝胶的典型热可逆性没有改变。有机凝胶是在两种温度(5°C和25°C)下生产的,具有两种浓度的12-HSA(5%和20%),可以用作API载体。两种溶解介质分别用于有无酶(pH 1.2和6.8),用于EFV释放定量。从双凝胶胶囊(直径从2500到3000μm)的EFV释放曲线基本上与核心中有机胶凝剂的量,藻酸盐膜的存在以及该膜的状态物理性质(水合或干燥)有关。在存在外部膜的情况下,在酸性pH下,EFV的释放减少了50%。在模拟胃液中,释放比在pH 6.8(模拟肠液)下的释放要慢。在肠道中,膜失去了保护功能,有机凝胶的核心开始控制EFV的释放。观察到两种释放机制:侵蚀和扩散,这可以通过Korsmeyer-Peppas模型来解释。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号